About AnaptysBio, Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Address: 10421 Pacific Center Court, San Diego, CA, United States, 92121
AnaptysBio, Inc News and around…
Latest news about AnaptysBio, Inc (ANAB) common stock and company :
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.05 per unit.
Market forces rained on the parade of AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders today, when the analysts downgraded...
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in Q1 2023 SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT. A live audio webcast of the presentation will be ava
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.26 per unit.
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But that...
Gainers Kiromic BioPharma (NASDAQ:KRBP) shares increased by 151.7% to $0.7 during Tuesday's pre-market session. The ...
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m. ET
During theThursday's session, 100 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week ...
During Friday's session, 59 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week ...
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went ...
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.69 per unit.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in B. Riley Financial Inc (RILY), where a total of 3,042 contracts have traded so far, representing approximately 304,200 underlying shares..
One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Crocs Inc (CROX), where a total of 17,406 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 128.8% of CROX's average daily trading volume over the past month of 1.4 million shares..
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing imsidolimab GEMINI-1 Phase 3 trial in GPP is anticipated in Q4 2023Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in H1 2023Ended Q1 2022 with approximately $596.8 million in cash with anticipated 2022 net cash burn of $90 to $
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Seeks FDA Emergency ...
AnaptysBio Inc(NASDAQ: ANAB)announced topline datafrom a Phase 1 trial of ANB032, an anti-BTLA agonist ...
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trialsANB032 IND filing in an initial proof-of-concept Phase 2 trial is anticipated in the second half of 2022Imsidolimab (anti-IL-36R Ab) top-line data from the Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in the third quarter of 2022 SAN DI
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.16 per unit.
Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Keytruda ...
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AnaptysBio Inc's(NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acnedid not demonstrate ...
AnaptysBio, Inc (ANAB) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
